Daily Adaptive Radiation Therapy an Individualized Approach for Carcinoma of the Cervix (ARTIA-Cervix)
Daily Adaptive External Beam Radiation Therapy in the Treatment of Carcinoma of the Cervix: A Prospective Trial of an Individualized Approach for Intestinal Toxicity Reduction (ARTIA-Cervix)
Sponsor: Varian, a Siemens Healthineers Company
This NA trial investigates Cervical Cancer by FIGO Stage 2018 and is currently actively recruiting participants. Varian, a Siemens Healthineers Company leads this study, which shows 10 recorded versions since 2022 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
10 versions recorded-
Oct 2025 — Present [monthly]
Recruiting NA
-
Dec 2024 — Oct 2025 [monthly]
Recruiting NA
-
Sep 2024 — Dec 2024 [monthly]
Recruiting NA
-
Jul 2024 — Sep 2024 [monthly]
Recruiting NA
-
Jun 2024 — Jul 2024 [monthly]
Recruiting NA
▶ Show 5 earlier versions
-
Sep 2023 — Jun 2024 [monthly]
Recruiting NA
-
Apr 2023 — Sep 2023 [monthly]
Recruiting NA
-
Jul 2022 — Apr 2023 [monthly]
Recruiting NA
Status: Not Yet Recruiting → Recruiting
-
Apr 2022 — Jul 2022 [monthly]
Not Yet Recruiting NA
-
Feb 2022 — Apr 2022 [monthly]
Not Yet Recruiting NA
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Varian, a Siemens Healthineers Company
For direct contact, visit the study record on ClinicalTrials.gov .